D Mischoulon

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder
    David Mischoulon
    1 Bowdoin Sq, 6th Floor, Massachusetts General Hospital, Boston, MA 02114
    J Clin Psychiatry 75:370-6. 2014
  2. doi Omega-3 fatty acids in psychiatry
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 1 Bowdoin Square, 6th Floor, Boston, MA 02114, USA
    Psychiatr Clin North Am 36:15-23. 2013
  3. pmc Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    CNS Spectr 17:76-86. 2012
  4. pmc Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder
    David Mischoulon
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 73:843-8. 2012
  5. ncbi Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 73:353-7. 2012
  6. ncbi "The Matrix": An allegory of the psychoanalytic journey
    David Mischoulon
    Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
    Acad Psychiatry 28:71-7. 2004
  7. ncbi Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians
    D Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Can J Psychiatry 45:476-81. 2000
  8. ncbi Report of two double-blind randomized placebo-controlled pilot studies of a carbohydrate-rich nutrient mixture for treatment of seasonal affective disorder (SAD)
    David Mischoulon
    Clinical Research Center, Massachusetts Institute of Technology, Cambridge, MA, USA
    CNS Neurosci Ther 16:13-24. 2010
  9. pmc A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder
    David Mischoulon
    Massachusetts General Hospital, Depression Clinical and Research Program, Boston, MA 02114, USA
    J Clin Psychiatry 70:1636-44. 2009
  10. ncbi A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States
    Eur Neuropsychopharmacol 18:639-45. 2008

Research Grants

  1. Omega-3 Fatty Acids in the Treatment of Depression
    David Mischoulon; Fiscal Year: 2005
  2. Omega-3 Fatty Acids for Treatment of Major Depression
    David Mischoulon; Fiscal Year: 2006
  3. Omega-3 Fatty Acids for Treatment of Major Depression
    David Mischoulon; Fiscal Year: 2007
  4. Omega-3 Fatty Acids for Treatment of Major Depression
    David Mischoulon; Fiscal Year: 2009
  5. Omega-3 Fatty Acids for Treatment of Major Depression
    David Mischoulon; Fiscal Year: 2010

Detail Information

Publications66

  1. ncbi A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder
    David Mischoulon
    1 Bowdoin Sq, 6th Floor, Massachusetts General Hospital, Boston, MA 02114
    J Clin Psychiatry 75:370-6. 2014
    ..To examine the comparative antidepressant efficacy of S-adenosyl-L-methionine (SAMe) and escitalopram in a placebo-controlled, randomized, double-blind clinical trial...
  2. doi Omega-3 fatty acids in psychiatry
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 1 Bowdoin Square, 6th Floor, Boston, MA 02114, USA
    Psychiatr Clin North Am 36:15-23. 2013
    ....
  3. pmc Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    CNS Spectr 17:76-86. 2012
    ..To examine the prevalence of the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and the A2756G polymorphism of methionine synthase (MS), and their impact on antidepressant response...
  4. pmc Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder
    David Mischoulon
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 73:843-8. 2012
    ....
  5. ncbi Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 73:353-7. 2012
    ....
  6. ncbi "The Matrix": An allegory of the psychoanalytic journey
    David Mischoulon
    Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
    Acad Psychiatry 28:71-7. 2004
    ..The Matrix" has been a huge commercial and critical success and has spawned a series of books and essays exploring the philosophical and religious themes in the story...
  7. ncbi Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians
    D Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Can J Psychiatry 45:476-81. 2000
    ..To examine treatment practices in cases where selective serotonin reuptake inhibitors (SSRIs) are ineffective...
  8. ncbi Report of two double-blind randomized placebo-controlled pilot studies of a carbohydrate-rich nutrient mixture for treatment of seasonal affective disorder (SAD)
    David Mischoulon
    Clinical Research Center, Massachusetts Institute of Technology, Cambridge, MA, USA
    CNS Neurosci Ther 16:13-24. 2010
    ..The drink mix was well tolerated and treatment adherence was high. Both the active and placebo intervention were effective in alleviating symptoms of SAD. Replication studies in larger samples appear warranted...
  9. pmc A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder
    David Mischoulon
    Massachusetts General Hospital, Depression Clinical and Research Program, Boston, MA 02114, USA
    J Clin Psychiatry 70:1636-44. 2009
    ..To examine the efficacy and tolerability of ethyl-eicosapentaenoate (EPA-E) monotherapy for major depressive disorder (MDD)...
  10. ncbi A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States
    Eur Neuropsychopharmacol 18:639-45. 2008
    ..05). For completers and intent-to-treat subjects, plasma DHA increased significantly (p<0.05), EPA had little change (p>0.05), and n-6/n-3 decreased significantly (p<0.05). DHA may be effective for depression at lower doses...
  11. ncbi The role of folate in depression and dementia
    David Mischoulon
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:28-33. 2007
    ..Supplementation with the active form of folate, methyltetrahydrofolate, which is more readily absorbed, may be effective in the prevention and treatment of both depression and dementia...
  12. pmc Depression and eating disorders: treatment and course
    David Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Affect Disord 130:470-7. 2011
    ..We examined the course of major depressive disorder (MDD) and predictors of MDD recovery and relapse in a longitudinal sample of women with eating disorders (ED)...
  13. ncbi Update and critique of natural remedies as antidepressant treatments
    David Mischoulon
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, WAC 812, 15 Parkman Street, Boston, MA 02114, USA
    Psychiatr Clin North Am 30:51-68. 2007
    ..Finally, as with all psychotropic agents, natural medications should be used preferably under the supervision of a physician...
  14. ncbi Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression
    D Mischoulon
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman St, WAC 812, Boston, MA 02114, USA
    J Psychosom Res 49:183-7. 2000
    ..We wished to determine whether anemia or macrocytosis predict hypofolatemia, low B12, or refractoriness to antidepressants...
  15. ncbi Management of major depression in the primary care setting
    D Mischoulon
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Psychother Psychosom 70:103-7. 2001
    ..We wished to determine how PCPs in a community clinic setting initially manage patients newly diagnosed with major depression...
  16. ncbi Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence
    David Mischoulon
    Harvard Medical School, Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
    Am J Clin Nutr 76:1158S-61S. 2002
    ..Head-to-head comparisons with newer antidepressants should help to clarify SAMe's place in the psychopharmacologic armamentarium...
  17. ncbi An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding
    David Mischoulon
    Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    Psychiatry Res 116:151-61. 2002
    ..The effectiveness of nefazodone for depression with anger attacks may be related to widespread changes in 5HT2 receptor BP...
  18. pmc Update and critique of natural remedies as antidepressant treatments
    David Mischoulon
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Suite 401, Boston, MA 02114, USA
    Obstet Gynecol Clin North Am 36:789-807, x. 2009
    ..There are limited data regarding safety in pregnancy and during lactation, and caution is therefore recommended in women who are pregnant or breastfeeding...
  19. ncbi Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day
    R H Perlis
    Depression Clinical and Research Program, Massachusetts General Hospital, WACC 812, 15 Parkman Street, Boston, MA 02114, USA
    Acta Psychiatr Scand 108:432-8. 2003
    ..Factors moderating response to these next-step interventions are not well-studied...
  20. ncbi The potential relationship between levels of perceived stress and subtypes of major depressive disorder (MDD)
    A H Farabaugh
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA WAC 812, USA
    Acta Psychiatr Scand 110:465-70. 2004
    ....
  21. ncbi A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment
    David Mischoulon
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
    Depress Anxiety 19:43-50. 2004
    ..Our study suggests that the rate of negative outcomes with nefazodone is no different whether patients have recently failed an SSRI...
  22. doi Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants
    Marlene P Freeman
    Perinatal and Reproductive Psychiatry Program, Massachusetts General Hospital, 185 Cambridge St, 2nd Floor, Boston, MA 02114, USA
    J Clin Psychiatry 71:682-8. 2010
    ....
  23. ncbi Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
    Eur Neuropsychopharmacol 14:135-42. 2004
    ..We then propose possible mechanisms that would account for the relationship between elevated cholesterol and treatment non-response in MDD...
  24. doi A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, 55 Fruit St, Bulfinch 351, Boston, MA 02114, USA
    J Clin Psychiatry 72:473-9. 2011
    ..In this post hoc analysis of patients with insomnia and comorbid anxious depression, eszopiclone cotherapy with a selective serotonin reuptake inhibitor (SSRI) was compared with placebo cotherapy...
  25. ncbi Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression
    Andrew A Nierenberg
    Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Biol Psychiatry 64:455-60. 2008
    ..This study describes the outcome of VNS for bipolar TRD patients participating in the acute and longitudinal pivotal trials and compares their outcome with unipolar TRD patients in the same trials...
  26. ncbi Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Psychiatry Res 161:116-20. 2008
    ..Studies examining whether specific treatment strategies are more effective than the selective serotonin reuptake inhibitors for MDD patients with high levels of co-morbid psychic and somatic anxiety symptoms are warranted...
  27. doi A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction
    Christina M Dording
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    CNS Neurosci Ther 14:182-91. 2008
    ..Maca was well tolerated. Maca root may alleviate SSRI-induced sexual dysfunction, and there may be a dose-related effect. Maca may also have a beneficial effect on libido...
  28. doi Frontal EEG predictors of treatment outcome in major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, United States
    Eur Neuropsychopharmacol 19:772-7. 2009
    ..To investigate the role of frontal EEG as predictor of clinical response to SSRIs or venlafaxine in major depressive disorder (MDD)...
  29. doi Evidence for folate in combination with antidepressants at initiation of therapy
    Maurizio Fava
    Department of Psychiatry, Harvard Medical School and Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 71:e31. 2010
    ..An agent such as folate, which is a naturally occurring B vitamin and is necessary for the synthesis of the trimonoamine neurotransmitters implicated in depression, may enhance the effects of a traditional antidepressant...
  30. doi Folate in depression: efficacy, safety, differences in formulations, and clinical issues
    Maurizio Fava
    Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 351, Boston, MA 02114, USA
    J Clin Psychiatry 70:12-7. 2009
    ..Several forms of folate appear to be safe and efficacious in some individuals with major depressive disorder, but more information is needed about dosage and populations most suited to folate therapy...
  31. ncbi Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment
    Amy Farabaugh
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA USA
    Ann Clin Psychiatry 22:166-71. 2010
    ....
  32. doi S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial
    George I Papakostas
    Center for Treatment Resistant Depression, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman St, Boston, MA 02114, USA
    Am J Psychiatry 167:942-8. 2010
    ....
  33. pmc Low-dose transdermal testosterone augmentation therapy improves depression severity in women
    Karen K Miller
    Neurendocrine Research Program in Women s Health, Neuendocrine Unit, Massachusetts General Hospital, Boston, MA, USA
    CNS Spectr 14:688-94. 2009
    ..However, the effects of low-dose testosterone as augmentation therapy in women with treatment-resistant depression have not been studied...
  34. doi Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report
    Marlene P Freeman
    Center for Women s Mental Health, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychiatry 71:669-81. 2010
    ..To review selected complementary and alternative medicine (CAM) treatments for major depressive disorder (MDD)...
  35. doi Deficits in psychological well-being and quality-of-life in minor depression: implications for DSM-V
    Andrew A Nierenberg
    Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    CNS Neurosci Ther 16:208-16. 2010
    ..To examine deficits in psychological well-being (PWB) and quality-of-life (QOL) in minor depressive disorder (Min D)...
  36. ncbi Predictors of stable personality disorder diagnoses in outpatients with remitted depression
    Amy Farabaugh
    Depression and Clinical Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    J Nerv Ment Dis 190:248-56. 2002
    ....
  37. ncbi S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine
    Jonathan E Alpert
    Depression Clinical and Research Program, Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:661-4. 2004
    ..The purpose of this open trial was to evaluate the safety, tolerability, and efficacy of oral S-adenosyl-L-methionine as an antidepressant adjunct among partial and nonresponders to serotonin reuptake inhibitors or venlafaxine...
  38. ncbi Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 65:1096-8. 2004
    ....
  39. ncbi Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 65:1090-5. 2004
    ....
  40. ncbi Integrating psychiatry and primary care improves acceptability to mental health services among Chinese Americans
    Albert Yeung
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Gen Hosp Psychiatry 26:256-60. 2004
    ..3, P<.001) in the previous 12 months. Integrating psychiatry and primary care is effective in improving access to mental health services and in increasing treatment engagement among low-income immigrant Chinese Americans...
  41. ncbi Prevalence of major depressive disorder among Chinese-Americans in primary care
    Albert Yeung
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Gen Hosp Psychiatry 26:24-30. 2004
    ..6% +/- 0.06. MDD is common among Asian-Americans in primary care settings. The prevalence of MDD is comparable to or higher than those found in the U.S. nonminority populations...
  42. ncbi Quality of life assessments in major depressive disorder: a review of the literature
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Gen Hosp Psychiatry 26:13-7. 2004
    ..Exploring the impact of these modalities on psychosocial function and quality of life in MDD are necessary to help translate clinical response into restoration of psychosocial function and to thus further improve the standard of care...
  43. ncbi Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment
    Roy H Perlis
    Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA
    Biol Psychiatry 54:879-83. 2003
    ..This study investigated a possible association with treatment-emergent insomnia or agitation...
  44. ncbi Serum cholesterol and serotonergic function in major depressive disorder
    George I Papakostas
    Depression Clinical and Research Program, Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
    Psychiatry Res 118:137-45. 2003
    ....
  45. ncbi The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists
    Christina M Dording
    Depression Clinical and Research Group, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 14:143-7. 2002
    ..In our opinion, this practice may reflect the relative lack of research studies on the role of adjunctive treatments in the management of SSRI-induced side effects and/or the tendency to favor monotherapy over polypharmacy...
  46. ncbi An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses
    John D Matthews
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 63:1164-70. 2002
    ..The aim of this study was to assess, by interim analyses, the efficacy of the atypical antipsychotic agent olanzapine in combination with the selective serotonin reuptake inhibitor antidepressant agent fluoxetine...
  47. ncbi Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression
    Jonathan E Alpert
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA
    Ann Clin Psychiatry 14:33-8. 2002
    ..Leucovorin appears to be modestly effective as an adjunct among SSRI-refractory depressed individuals with normal folate levels. The application of leucovorin as an adjunct in the setting of refractory depression deserves further study...
  48. ncbi The overlap between personality disorders and major depressive disorder (MDD)
    Amy Farabaugh
    The Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Ann Clin Psychiatry 16:217-24. 2004
    ..Research studies have focused attention on the importance of the comorbidity of personality disorders and depression...
  49. ncbi The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients
    Amy Farabaugh
    Depression Clinical and Research Program, Massachusetts General Hospital, MA WAC 812, USA
    Int Clin Psychopharmacol 20:87-91. 2005
    ..In conclusion, the presence of early improvement on the HAMD-17 item concerning fatigue and general somatic symptoms is significantly predictive of achieving remission at endpoint with active study treatment but not with placebo...
  50. ncbi The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Int J Neuropsychopharmacol 8:523-8. 2005
    ..05). In conclusion, low serum folate levels were found to be associated with a delayed onset of clinical improvement during treatment with fluoxetine in MDD by, on average, 1.5 wk...
  51. ncbi Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD
    Amy Farabaugh
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Depress Anxiety 24:433-9. 2007
    ..This finding suggests that dysfunctional attitudes that persist beyond remission of MDD may be a marker for certain personality disorders that are stable across long-term treatment...
  52. ncbi Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis
    Amy H Farabaugh
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, USA USA
    Hum Psychopharmacol 21:221-5. 2006
    ..This study examines the relationship between cognitive factors and TDR and PPR to fluoxetine...
  53. ncbi The combination of duloxetine and bupropion for treatment-resistant major depressive disorder
    George I Papakostas
    Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Boston, 02114, USA
    Depress Anxiety 23:178-81. 2006
    ..Although preliminary, these results suggest a possible role for the combination of duloxetine and bupropion for TRD...
  54. ncbi Outcomes of recognizing depressed Chinese American patients in primary care
    Albert Yeung
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, Massachusetts 02114, USA
    Int J Psychiatry Med 35:213-24. 2005
    ..This study aims to examine the effect of identifying Chinese American patients as having major depressive disorder (MDD) to their primary care physicians (PCPs) on the latter's attention given to the treatment of depression...
  55. ncbi Anger attacks in major depressive disorder and serum levels of homocysteine
    Renerio Fraguas
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 60:270-4. 2006
    ..Increased levels of homocysteine have been associated with anger and depression separately. We investigated the association of anger attacks in major depressive disorder (MDD) with serum levels of homocysteine...
  56. ncbi An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder
    Dan V Iosifescu
    Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 66:1038-42. 2005
    ..In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment...
  57. ncbi Relationships between major depressive disorder and comorbid anxiety and personality disorders
    Amy Farabaugh
    Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Compr Psychiatry 46:266-71. 2005
    ....
  58. ncbi A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 25:441-7. 2005
    ..This study looks to compare the antidepressant efficacy and safety of a standardized extract of St John's wort with both placebo and fluoxetine...
  59. doi SAMe and sexual functioning
    C M Dording
    Depression Clinical and Research Program, Massachusetts General Hospital, Department of Psychiatry, Massachusetts General Hospital, 1 Bowdoin Square, 6th Floor, Boston, MA 02114, USA
    Eur Psychiatry 27:451-4. 2012
    ..Consequently, it is vital to develop novel treatments that target antidepressant-induced sexual dysfunction...
  60. ncbi Does psychiatry residency training reflect the "real world" of psychiatry practice? A survey of residency graduates
    Timothy Petersen
    Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Acad Psychiatry 31:281-9. 2007
    ..The authors determine whether Massachusetts General Hospital's residency graduates believed their training reflected their current practice activities...
  61. doi Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder
    Y Levkovitz
    Psychiatry Department, Shalvata Mental Health Center, Tel Aviv University, Hamargoa 4, POB 94, Tel Aviv, Israel
    Eur Psychiatry 27:518-21. 2012
    ....
  62. ncbi Functioning and interpersonal relationships as predictors of response in treatment-resistant depression
    George I Papakostas
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
    Compr Psychiatry 44:44-50. 2003
    ..Beyond a history of nonresponse to antidepressants, long-term occupational function may be a predictor of outcome in the treatment of TRD...
  63. doi Clinical features and functioning of patients with minor depression
    Robert H Howland
    Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Psychother Psychosom 77:384-9. 2008
    ..The two essential features of minor depression are that it has fewer symptoms than major depression and that it is less chronic than dysthymia. This study describes the clinical features and functioning of outpatients with minor depression...
  64. ncbi Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry
    Marlene P Freeman
    Women s Mental Health Program, Department of Psychiatry, University of Arizona College of Medicine, Tucson 85724 5002, USA
    J Clin Psychiatry 67:1954-67. 2006
    ..To determine if the available data support the use of omega-3 essential fatty acids (EFA) for clinical use in the prevention and/or treatment of psychiatric disorders...
  65. ncbi Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo
    Harald Murck
    Lichtwer Pharma GmbH, Berlin, Germany
    Int J Neuropsychopharmacol 8:215-21. 2005
    ..These data are based on a small sample size and must be considered tentative. A characterization of vegetative features of patients with depression could lead to an overall increased effect size in the treatment with HE...
  66. ncbi Acupuncture for major depressive disorder: has its efficacy been disproved?
    Albert Yeung
    J Clin Psychiatry 68:1617; author reply 1617-8. 2007

Research Grants6

  1. Omega-3 Fatty Acids in the Treatment of Depression
    David Mischoulon; Fiscal Year: 2005
    ..It is hoped that this project will provide the critical fund of basic knowledge and practical experience necessary to aid the candidate in becoming an independent investigator. ..
  2. Omega-3 Fatty Acids for Treatment of Major Depression
    David Mischoulon; Fiscal Year: 2006
    ..e. integrates biological findings with treatment in order to have a direct impact on the clinical practice of psychiatry. ..
  3. Omega-3 Fatty Acids for Treatment of Major Depression
    David Mischoulon; Fiscal Year: 2007
    ..e. integrates biological findings with treatment in order to have a direct impact on the clinical practice of psychiatry. ..
  4. Omega-3 Fatty Acids for Treatment of Major Depression
    David Mischoulon; Fiscal Year: 2009
    ..e. integrates biological findings with treatment in order to have a direct impact on the clinical practice of psychiatry. ..
  5. Omega-3 Fatty Acids for Treatment of Major Depression
    David Mischoulon; Fiscal Year: 2010
    ..e. integrates biological findings with treatment in order to have a direct impact on the clinical practice of psychiatry. ..